Central serous chorioretinopathy (CSC) is a relatively common posterior segment disease characterized by serous detachment of the neurosensory retina. Altered function of the retinal pigment epithelium (RPE) and choroidal vascular hyperpermeability suggestive of choroidal vascular compromise have been thought to play important roles in the pathogenesis of CSC [1,2]. CSC typically affects middle aged adults between 30 and 50 years and is more prevalent in men, with the peak annual incidence in men being between the years 35 and 39 [3,4]. Patients with CSC may experience sudden onset of blurred vision, metamorphopsia, decreased color vision and central scotoma. While acute CSC usually resolves spontaneously within 2-6 months, the chronic subtype with recurrent or persistent episodes may result in permanent visual loss with structural RPE damage [5,6].